FDA Discusses Roadmap for Converting Prescription Drugs to Nonprescription Drugs, Including Sanofi's Cialis, Utilizing the ACNU System
Background and Regulatory Modernization of ACNU Implementation
The U.S. Food and Drug Administration (FDA) is actively promoting policies to transition prescription drugs to nonprescription drugs (Nonprescription Drugs) to significantly improve access to medications for patients with chronic diseases and support patient-driven health management. In particular, the 'Additional Conditions for Nonprescription Use (ACNU)' guideline, finalized in December 2024 and fully implemented in May 2025, serves as an innovative legal framework that enables the transition from prescription drugs to over-the-counter (OTC) drugs. This goes beyond simply changing drug classifications; it reflects the FDA's intention to redefine regulatory standards to ensure that consumers can safely self-select and use medications without misuse, even without a doctor's prescription, at pharmacies or online. This regulatory change is expected to function as an important social mechanism to alleviate the increasing healthcare costs in the United States and fill the gaps in primary healthcare services.
Key Companies' OTC Transition Strategies
In this context, Sanofi (SNY), through its consumer healthcare division Opella, is actively pursuing the OTC switch of Cialis (generic name: tadalafil, a PDE-5 inhibitor), a leading treatment for erectile dysfunction. Following the FDA's official lifting of the hold on the Actual Use Trial (AUT) for Cialis in January 2025, the company has begun accelerating the final clinical stage for over-the-counter sales without a prescription. Furthermore, Perrigo (PRGO), building on its success in obtaining the first OTC approval for Opill, a daily oral contraceptive (generic name: norgestrel, a progestin receptor agonist) in 2023, is seeking to expand its pipeline by incorporating ACNU. Major pharmaceutical companies are closely monitoring this OTC transition strategy as a way to extend the lifecycle of original blockbuster drugs facing patent expiration.
Integration of Digital Health Technology and Challenges
To obtain ACNU approval, companies must mandatorily incorporate digital tools that help consumers determine the suitability of the drug themselves without a doctor's diagnosis. This includes mobile applications (Apps), pharmacy kiosks, and intelligent self-screening systems that check the patient's condition in real-time. However, the industry is concerned that the digital divide may exacerbate healthcare disparities among the elderly and disadvantaged populations who are not adept at using smart devices. Therefore, this public meeting focused on improving the intuitiveness of digital surveys and regulatory guidelines for protecting personal information.
Creation of New Markets and Investment Prospects
The global Rx-to-OTC switch market is estimated to reach approximately $43.9 billion (approximately 60 trillion Korean Won) by 2026, and the overall OTC market is recording a stable growth rate of 5-7% per year. Regulatory easing is creating an ecosystem in which startups and digital health solution providers can enter new markets through partnerships with pharmaceutical companies. From an investor's perspective, it is important to focus on the potential of complex digital solution combination models beyond simple drug sales revenue. As the FDA's final guidelines are finalized, diversification of drug distribution channels and a rapid shift in the e-commerce market are expected, so a long-term portfolio adjustment is necessary.
The establishment of ACNU guidelines by regulatory authorities provides direct investment opportunities for global pharmaceutical companies seeking new growth engines in response to patent expirations and IT venture companies developing related solutions. In the short term, the progress and approval of the Actual Use Trial (AUT) for Sanofi's Cialis, following the lifting of the clinical hold, will serve as a benchmark for the entire market, and in the medium to long term, the scope of the switch is expected to expand to chronic disease areas such as hyperlipidemia. For researchers and developers, the ability to design algorithms that can control consumer self-diagnosis and misuse, beyond simply demonstrating drug efficacy, will become a key competitive advantage. In the Rx-to-OTC conversion market, estimated at approximately $43.9 billion by 2026, technological collaboration with leaders such as Perrigo and the establishment of patent barriers will be key indicators in determining future market share.